USFDA has completed audit of Shilpa Medicare’s Jadcherla facility. The company has received ‘without 483’ for its SEZ formulations facility situated at Jadcherla near Hyderabad from the United States Food & Drug Administration (USFDA). USFDA’s 483 is a form issued to a company or management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The USFDA had conducted audit from July 18 to 26.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
